Marilyn Tan

Marilyn Tan, MD, Clinical Associate Professor, Department of Medicine, Division of Endocrinology, Gerontology, and Metabolism, Stanford University School of Medicine

Research Description: Dr. Tan served as the principal investigator for two phase 2 trials assessing the role of glucagon like peptide 1 (GLP1) antagonism in patients with post bariatric hypoglycemia. The first study involved a dose escalation trial to assess efficacy and pharmacokinetics for avexitide (formerly known as Exendin (9-39)). The second study was a multi-center placebo-controlled crossover trial (the PREVENT trial) assessing higher doses and longer-term use of avexitide in patients with post bariatric hypoglycemia. Dr. Tan is now starting a third trial with avexitide, extending the use of avexitide to patients with other forms of acquired hyperinsulinemic hypoglycemia. All 3 studies have sponsorship from Eiger Biopharmaceuticals. Dr. Tan was also the site primary investigator for the HARMONY outcomes trial with albiglutide in patients with type 2 diabetes and high cardiovascular risk. The aim was to assess the long term cardiovascular safety and possible benefits with GLP1 agonists. This study was sponsored by Glaxo Smith Kline. Dr. Tan was a co-investigator for the GI Dynamics Endosleeve trial assessing improvement in glycemic control with the Endo Barrier gastrointestinal liner system in obese patients with type 2 diabetes. This study is currently on hold by the FDA. Other collaborations include a clinical study of breath acetone measurements for patients with ketosis or ketoacidosis, a study of the immune response to pre-proinsulin in human type 1 diabetes, and integrative personal omics profiling for dynamic molecular phenotypes monitoring and medical risks assessment.

Selected relevant publications (Stanford DRC Members in BOLD):

  1. Craig CM, Lawler HM, Lee CJE, Tan M, Davis DB, Tong J, Gldowski M, Rogowitz E, Karaman R, McLaughlin TL, Porter L. PREVENT: A Randomized, Placebo-Controlled Crossover Trial of Avexitide for Treatment of Post-Bariatric Hypoglycemia. J Clin Endocrinol Metab. 2021 Feb 22. doi: 10.1210/clinem/dgab103. PMID: 33616643.

  2. Tan M, Lamendola C, Luong R, McLaughlin T, Craig C. Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia. Diabetes Obes Metab. 2020 Aug;22(8):1406-1416. doi: 10.1111/dom.14048. PMID: 32250530. 

  3. Schüssler-Fiorenza Rose SM, Contrepois K, ….., Limcaoco P, Ruiz C, Tan M, Butte AJ, Weinstock GM, Slavich GM, Sodergren E, McLaughlin TL, Haddad F, Snyder MP. A longitudinal big data approach for precision health. Nat Med. 2019 May;25(5):792-804. doi: 10.1038/s41591-019-0414-6. PMID: 31068711; PMCID: PMC6713274. 

  4. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019 Feb 1;12:209-215. doi: 10.2147/DMSO.S184437. PMID: 30787627; PMCID: PMC6363491.